Tofacitinib Targeting NK Cells to Protect ALS Motor Neurons
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for amyotrophic lateral sclerosis (ALS) are limited, and suppressing the immune system universally has had negligible effects or accelerated disease progression, while targeting specific immune cell populations has shown potential to alter the disease course.
Innovation Solution
Administering therapeutically effective amounts of the JAK kinase inhibitor tofacitinib to interfere with central nervous system-related natural killer (NK) cell levels and function, specifically inhibiting IL-15 signaling, IL-10 expression, IFN-γ expression, perforin levels, and NK cell migration, thereby reducing NK cell cytotoxicity against motor neurons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If universal immune system suppression is applied in ALS patients, then disease progression may be slowed, but treatment effectiveness is negligible or disease acceleration occurs
Solution Approach 1:
The patent applies segmentation by targeting specific immune cell populations (NK cells) rather than suppressing the entire immune system. This selective approach identifies and addresses the harmful subset (NK cells that attack motor neurons) while preserving beneficial immune functions, thereby resolving the contradiction between treatment effectiveness and disease acceleration.
Solution Approach 2:
The patent implements local quality by focusing therapeutic intervention on specific immune cell types (NK cells) with harmful properties in the CNS, while leaving other immune cells unaffected. This localized targeting achieves disease-specific treatment effectiveness without the harmful side effects of universal suppression.
2Reliability
If NK cell levels are increased to combat infection and cancer, then immune protection is improved, but motor neuron vulnerability increases due to lack of MHC I expression
Solution Approach 1:
The patent converts the harmful effect of NK cell-mediated cytotoxicity against motor neurons into a beneficial therapeutic outcome. By depleting NK cells or inhibiting their function, the patent transforms the previously harmful attack on motor neurons into protection, while maintaining NK cell functionality for combating infection and cancer through alternative mechanisms.
Solution Approach 2:
The patent applies parameter changes by modulating NK cell levels and function through therapeutic intervention. By changing the concentration and activity parameters of NK cells, the patent reduces their harmful cytotoxicity toward motor neurons while preserving their protective roles in immune defense.
3Reliability
If specific immune cell populations are targeted to alter disease course, then disease progression is slowed, but therapeutic specificity and safety must be maintained
Solution Approach 1:
The patent applies the extraction principle by isolating and targeting specific harmful immune cell populations (NK cells) from the overall immune system. This extraction approach allows selective removal of pathogenic cells while preserving the functional integrity of other immune cells, thereby achieving disease progression slowing with maintained therapeutic specificity and safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces CNS inflammation, prevents motor neuron vulnerability, and extends lifespan by targeting NK cells, without affecting protective CD4 T cell levels, thus providing a viable therapeutic option for ALS.
Implementation Method 1
Administering therapeutically effective amounts of the JAK kinase inhibitor tofacitinib to interfere with central nervous system-related natural killer (NK) cell levels and function
Implementation Method 2
tofacitinib was able to hinder and/or inhibit NK cell maintenance, expansion and cytotoxicity against other cells through one or more of hindering and/or inhibiting IL-15 signaling
Implementation Method 3
tofacitinib was able to hinder and/or inhibit NK cell maintenance, expansion and cytotoxicity against other cells through one or more of hindering and/or inhibiting IL-15 signaling, hindering and/or inhibiting IL-10 expression, hindering and/or inhibiting IFN-γ expression, reducing perforin levels
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 3A~3B
AI summary
Provided herein are methods for treating, delaying progression of, or reducing the severity of amyotrophic lateral sclerosis (ALS) in a subject through administration of therapeutically effective amounts of agents (e.g., JAK kinase inhibitors (e.g., tofacitinib)) capable of interfering with central nervous system related natural killer cell (NK) levels and function.